-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] In recent years, many places have carried out centralized procurement pilots for some varieties of Chinese patent medicines with high demand and high price
.
Among them, many regions have also formed purchasing alliances
.
For example, on September 14 last year, the Guangdong Provincial Drug Trading Center issued the "Guangdong Alliance Qingkailing and other 58 Pharmaceutical Groups Procurement Documents with Volume (Draft for Comment)"; then on September 19, Guangdong announced the launch of seven provincial Centralized procurement of patent medicine alliance
.
Since the beginning of this year, the Centralized Procurement Alliance of Chinese Patent Medicines has continued to develop.
For example, Hubei has recently led the 19-province alliance to open bids for the centralized procurement of Chinese patent medicines.
The centralized procurement results show that a total of 97 companies and 111 products have been selected, and the selected price has dropped by an average of 42.
27%.
Among them, products fell by more than 82%
.
It is worth noting that recently, the Guangdong Provincial Drug Trading Center issued the "Notice on Viewing the Information about Guangdong Alliance Qingkailing and other Chinese patent medicines for centralized purchase and registration products"
.
According to the notice, the members of the Guangdong Traditional Chinese Medicine Collective Procurement Alliance include Guangdong, Shanxi, Henan, Hainan, Ningxia, and Qinghai
.
This centralized purchase registration covers many common exclusive and non-exclusive Chinese patent medicine varieties, including: Qingkailing, Lanqin, Xingnaojing, Bailing, Shengmai, Fufang Danshen, Xuesaitong, Ginkgo biloba, Kanglaite , Lianhua Qingwen, Shenkang, Tanreqing, Xiyan and so
on.
The arrival of the 6-province Chinese patent medicine centralized procurement alliance, the industry generally believes that the relevant pharmaceutical companies will face the test of price reduction
.
In fact, in the past, the centralized procurement of medicines often led to a large drop in product prices
.
In addition, under the circumstance that medicines face price cuts, the analysis believes that Chinese patent medicine companies will also face risks such as large price fluctuations of raw medicinal materials and difficulty in cost control
.
In this context, how to control costs and ensure quality will become a major difficulty
.
In this regard, industry insiders suggested that pharmaceutical companies should first be prepared to actively meet regulatory requirements, such as building a Chinese herbal medicine planting base that complies with GAP specifications; at the same time, they should also increase R&D investment, improve quality standards, and accelerate the construction of a Chinese medicine standardization system , to form group standards, local standards, industry standards, national standards, international standards, and a multi-level, multi-dimensional, whole-process quality control system covering medicinal materials, intermediates, and finished products
.
It is reported that at present, many Chinese patent medicine-related enterprises have begun to try to increase investment in research and development, build standardized planting bases for Chinese medicinal materials, improve quality standards, and set up professional-level academic self-support promotion teams to meet the challenges
.
For example, China Resources Sanjiu has publicly stated earlier that it is studying the plan based on its own product conditions, and will pay attention to and formulate corresponding plans based on product grouping, application volume, and manufacturer competition
.
In addition, some people in the industry pointed out that it is necessary to pay attention to and strengthen the updating and upgrading of relevant pharmaceutical equipment, and design and develop equipment that can better ensure the quality of medicines and can save energy and increase efficiency according to the needs of Chinese patent medicine pharmaceuticals.
.
The analysis believes that under the background of the continuous advancement of the centralized procurement of proprietary Chinese medicines and the approach of national procurement, enterprises will have higher and higher requirements for cost control and quality, so more advanced technologies and equipment are needed for support
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, many regions have also formed purchasing alliances
.
For example, on September 14 last year, the Guangdong Provincial Drug Trading Center issued the "Guangdong Alliance Qingkailing and other 58 Pharmaceutical Groups Procurement Documents with Volume (Draft for Comment)"; then on September 19, Guangdong announced the launch of seven provincial Centralized procurement of patent medicine alliance
.
Since the beginning of this year, the Centralized Procurement Alliance of Chinese Patent Medicines has continued to develop.
For example, Hubei has recently led the 19-province alliance to open bids for the centralized procurement of Chinese patent medicines.
The centralized procurement results show that a total of 97 companies and 111 products have been selected, and the selected price has dropped by an average of 42.
27%.
Among them, products fell by more than 82%
.
It is worth noting that recently, the Guangdong Provincial Drug Trading Center issued the "Notice on Viewing the Information about Guangdong Alliance Qingkailing and other Chinese patent medicines for centralized purchase and registration products"
.
According to the notice, the members of the Guangdong Traditional Chinese Medicine Collective Procurement Alliance include Guangdong, Shanxi, Henan, Hainan, Ningxia, and Qinghai
.
This centralized purchase registration covers many common exclusive and non-exclusive Chinese patent medicine varieties, including: Qingkailing, Lanqin, Xingnaojing, Bailing, Shengmai, Fufang Danshen, Xuesaitong, Ginkgo biloba, Kanglaite , Lianhua Qingwen, Shenkang, Tanreqing, Xiyan and so
on.
The arrival of the 6-province Chinese patent medicine centralized procurement alliance, the industry generally believes that the relevant pharmaceutical companies will face the test of price reduction
.
In fact, in the past, the centralized procurement of medicines often led to a large drop in product prices
.
In addition, under the circumstance that medicines face price cuts, the analysis believes that Chinese patent medicine companies will also face risks such as large price fluctuations of raw medicinal materials and difficulty in cost control
.
In this context, how to control costs and ensure quality will become a major difficulty
.
In this regard, industry insiders suggested that pharmaceutical companies should first be prepared to actively meet regulatory requirements, such as building a Chinese herbal medicine planting base that complies with GAP specifications; at the same time, they should also increase R&D investment, improve quality standards, and accelerate the construction of a Chinese medicine standardization system , to form group standards, local standards, industry standards, national standards, international standards, and a multi-level, multi-dimensional, whole-process quality control system covering medicinal materials, intermediates, and finished products
.
It is reported that at present, many Chinese patent medicine-related enterprises have begun to try to increase investment in research and development, build standardized planting bases for Chinese medicinal materials, improve quality standards, and set up professional-level academic self-support promotion teams to meet the challenges
.
For example, China Resources Sanjiu has publicly stated earlier that it is studying the plan based on its own product conditions, and will pay attention to and formulate corresponding plans based on product grouping, application volume, and manufacturer competition
.
In addition, some people in the industry pointed out that it is necessary to pay attention to and strengthen the updating and upgrading of relevant pharmaceutical equipment, and design and develop equipment that can better ensure the quality of medicines and can save energy and increase efficiency according to the needs of Chinese patent medicine pharmaceuticals.
.
The analysis believes that under the background of the continuous advancement of the centralized procurement of proprietary Chinese medicines and the approach of national procurement, enterprises will have higher and higher requirements for cost control and quality, so more advanced technologies and equipment are needed for support
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
